deltatrials
Completed PHASE2 INTERVENTIONAL 5-arm NCT02336165

Phase 2 Study of Durvalumab (MEDI4736) in Patients With Glioblastoma

Phase 2 Study to Evaluate the Clinical Efficacy and Safety of MEDI4736 in Patients With Glioblastoma (GBM)

Sponsor: Cancer Research Institute, New York City

Conditions Glioblastoma
Interventions Bevacizumab Durvalumab Standard radiotherapy
Updated 17 times since 2017 Last updated: Oct 3, 2022 Started: Feb 26, 2015 Primary completion: Nov 30, 2018 Completion: Jul 6, 2021
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02336165, this PHASE2 trial focuses on Glioblastoma and remains completed. Sponsored by Cancer Research Institute, New York City, it has been updated 17 times since 2015, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Mar 2018 · 13 months · monthly snapshot~Mar 2018 – ~Jun 2018 · 3 months · monthly snapshot~Jun 2018 – ~Oct 2018 · 4 months · monthly snapshot~Oct 2018 – ~Nov 2018 · 31 days · monthly snapshot~Nov 2018 – ~Nov 2019 · 12 months · monthly snapshot~Nov 2019 – ~Jan 2020 · 2 months · monthly snapshot~Jan 2020 – ~Apr 2020 · 3 months · monthly snapshot~Apr 2020 – ~Jan 2021 · 9 months · monthly snapshot~Jan 2021 – ~Mar 2021 · 59 days · monthly snapshot~Mar 2021 – ~Sep 2021 · 6 months · monthly snapshot~Sep 2021 – ~Dec 2021 · 3 months · monthly snapshot~Dec 2021 – ~Nov 2022 · 11 months · monthly snapshot~Nov 2022 – ~Jul 2024 · 20 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 12 months · monthly snapshot

Change History

17 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  4. Nov 2022 — Jul 2024 [monthly]

    Completed PHASE2

  5. Dec 2021 — Nov 2022 [monthly]

    Completed PHASE2

▶ Show 12 earlier versions

  1. Sep 2021 — Dec 2021 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

  2. Mar 2021 — Sep 2021 [monthly]

    Active Not Recruiting PHASE2

  3. Jan 2021 — Mar 2021 [monthly]

    Active Not Recruiting PHASE2

  4. Apr 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE2

  5. Jan 2020 — Apr 2020 [monthly]

    Active Not Recruiting PHASE2

  6. Nov 2019 — Jan 2020 [monthly]

    Active Not Recruiting PHASE2

  7. Nov 2018 — Nov 2019 [monthly]

    Active Not Recruiting PHASE2

  8. Oct 2018 — Nov 2018 [monthly]

    Active Not Recruiting PHASE2

  9. Jun 2018 — Oct 2018 [monthly]

    Active Not Recruiting PHASE2

  10. Mar 2018 — Jun 2018 [monthly]

    Active Not Recruiting PHASE2

  11. Feb 2017 — Mar 2018 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  12. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE2

    First recorded

Feb 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Cancer Research Institute, New York City
  • Cure Brain Cancer Foundation, Australia
  • Ludwig Institute for Cancer Research
  • MedImmune LLC
Data source: Ludwig Institute for Cancer Research

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations